Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ibandronate sodium, quantity: 1.125 mg/ml (equivalent: ibandronic acid, qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - indicated for the treatment of: tumor-induced hypercalcaemia with or without metastases. metastatic bone disease in patients with breast cancer.

Ireland - English - HPRA (Health Products Regulatory Authority)

vaia s.a. - ibandronate sodium monohydrate - film coated tablet - 50 milligram

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mithra pharmaceuticals sa-nv - sodium ibandronate monohydrate 168,79 mg - eq. ibandronic acid 150 mg - film-coated tablet - ibandronic acid

United States - English - NLM (National Library of Medicine)

genentech, inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronic acid 150 mg - boniva is indicated for the treatment and prevention of osteoporosis in postmenopausal women. boniva increases bone mineral density (bmd) and reduces the incidence of vertebral fractures. the optimal duration of use has not been determined. the safety and effectiveness of boniva for the treatment of osteoporosis are based on clinical data of three years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. boniva is contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see warnings and precautions [5.1]) - inability to stand or sit upright for at least 60 minutes (see dosage and administration [2.2], and warnings and precautions [5.1]) - h

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - ibandronic sodium monohydrate - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - ibandronic sodium monohydrate - solution for infusion - 1mg/1ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sodium ibandronate monohydrate 168,75 mg - eq. ibandronic acid 150 mg - film-coated tablet - ibandronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

vaia s.a. - ibandronate sodium monohydrate - film coated tablet - 150 milligram

United States - English - NLM (National Library of Medicine)

genentech, inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronic acid 3 mg in 3 ml - boniva injection is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, boniva increases bone mineral density (bmd) and reduces the incidence of vertebral fractures [see clinical studies (14)] . the safety and effectiveness of boniva for the treatment of osteoporosis are based on clinical data of one year duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. boniva is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.1)] - known hypersensitivity to boniva injection or to any of its excipients. cases of anaphylaxis, including fatal events, have been

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronate sodium 150 mg - enter section text here boniva is indicated for the treatment and prevention of osteoporosis in postmenopausal women. boniva increases bone mineral density (bmd) and reduces the incidence of vertebral fractures. -   abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see upper gastrointestinal adverse reactions [5.1]) - inability to stand or sit upright for at least 60 minutes (see dosing instructions [2.2], upper gastrointestinal adverse reactions [5.1]) - hypocalcemia (see warnings and precautions [5.2]) - known hypersensitivity to boniva or to any of its excipients (see adverse reactions [6.2]). enter section text here there are no adequate and well-controlled studies in pregnant women. boniva should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. bisphosphonates are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. the extent of bisphosph